Echo Therapeutics’ Symphony(TM) System for Needle-Free Continuous Glucose Monitoring is Highlighted in Assembly Magazine’s January 2011 Issue

January 11, 2011

FRANKLIN, Mass., Jan. 11, 2011 /PRNewswire/ — Echo Therapeutics, Inc. (OTC Bulletin Board: ECTE), a company developing its needle-free Symphony(TM) tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system and its Prelude(TM) SkinPrep System for transdermal drug delivery, today announced that its Symphony System was featured in the cover story of Assembly Magazine’s January 2011 issue.

“We are pleased to have our Symphony System profiled by Assembly Magazine,” said Chairman, President and CEO Patrick T. Mooney, M.D., of Echo. “Diabetics need lighter, smaller, and less invasive devices and Symphony has all those attributes in its needle-free, wireless, continuous glucose monitoring system.”

The Assembly Magazine article can be found at http://bit.ly/i7wc2f

The Assembly Magazine article discussed the substantial increase in the number of medical devices manufactured for diabetes patients. The article said, “medical device engineers are scrambling to develop products that are less invasive, easier to use and cheaper to mass-produce.”

Assembly Magazine has more than 60,000 subscribers in more than 37,000 locations. It is read by manufacturing engineers, design engineers, and manufacturing and design managers.

The Symphony System was most recently featured in a Diabetes Health magazine article, entitled, “Echo Therapeutics’ Needle-Free Symphony Continuous Glucose Monitoring System,” which described in detail the advantages of the Symphony System. The Diabetes Health magazine article can be found at http://bit.ly/emcDw2

About Echo Therapeutics

Echo Therapeutics is developing the Symphony tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system for patients with diabetes and for use in hospital critical care units. Echo is also developing its needle-free Prelude SkinPrep System as a platform technology for enhanced skin permeation for delivery of topical pharmaceuticals.

Cautionary Statement Regarding Forward Looking Statements

The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to regulatory approvals and the success of Echo’s and its partners’ ongoing studies, including the efficacy of Echo’s Symphony tCGM and Prelude SkinPrep Systems, the failure of future development and preliminary marketing efforts related to Echo’s Symphony tCGM and Prelude SkinPrep Systems, Echo’s ability to secure additional commercial partnering arrangements, risks and uncertainties relating to Echo’s and its partners’ ability to develop, market and sell diagnostic and transdermal drug delivery products based on its skin permeation platform technologies, including the Symphony tCGM and Prelude SkinPrep Systems, the availability of substantial additional equity or debt capital to support its research, development and product commercialization activities, and the success of its research, development, regulatory approval, marketing and distribution plans and strategies, including those plans and strategies related to its Symphony tCGM and Prelude SkinPrep Systems. These and other risks and uncertainties are identified and described in more detail in Echo’s filings with the Securities and Exchange Commission, including, without limitation, its annual report on Form 10-K for the year ended December 31, 2009, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. Echo undertakes no obligation to publicly update or revise any forward-looking statements.

Connect with Echo Therapeutics:

    For More Information:
    Patrick T. Mooney, M.D.                   Media: Richard Stern
    Chairman and Chief Executive Officer      Stern & Co.
    (508)-530-0329                            (212) 888-0044

SOURCE Echo Therapeutics, Inc.

Source: newswire

comments powered by Disqus